Logo

IMNN

Imunon, Inc.

IMNN

Imunon, Inc. • NASDAQ
$4.12 ▲ 6.74% (+0.26)
Market Cap $10.39 M
52w High $41.22
52w Low $3.56
Dividend Yield 0%
P/E -0.33
Volume 17.32K
Outstanding Shares 2.52M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.309M ▲ $-3.429M ▼ 0% $-1.16 ▲ $-3.262M ▼
Q2-2025 $0 $2.603M ▲ $-2.741M ▲ 0% $-1.87 ▲ $-2.576M ▲
Q1-2025 $0 $1.98M ▼ $-4.102M ▼ 0% $-3.676 ▼ $-4.079M ▼
Q4-2024 $0 $3.981M ▲ $-4.057M ▲ 0% $-3.65 ▲ $-3.892M ▲
Q3-2024 $0 $1.668M $-4.845M 0% $-4.375 $-4.897M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.251M ▲ $8.988M ▲ $4.906M ▼ $4.082M ▲
Q2-2025 $4.729M ▲ $8.788M ▲ $6.128M ▼ $2.66M ▲
Q1-2025 $2.872M ▼ $6.862M ▼ $6.41M ▲ $452.028K ▼
Q4-2024 $5.873M ▼ $9.717M ▼ $5.473M ▼ $4.244M ▼
Q3-2024 $10.312M $14.391M $6.199M $8.192M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.429M ▼ $-4.441M ▼ $0 ▲ $4.963M ▲ $522.153K ▼ $-4.441M ▼
Q2-2025 $-2.741M ▲ $-2.951M ▼ $-17.331K ▲ $4.826M ▲ $1.857M ▲ $-2.969M ▲
Q1-2025 $-4.102M ▼ $-2.847M ▲ $-259.652K ▼ $105.692K ▲ $-3.001M ▲ $-3.107M ▲
Q4-2024 $-4.057M ▲ $-4.421M ▼ $-14.907K ▼ $-3.277K ▼ $-4.439M ▼ $-4.436M ▼
Q3-2024 $-4.845M $-4.055M $-2.879K $9.064M $5.005M $-4.058M

Five-Year Company Overview

Income Statement

Income Statement Imunon is a classic clinical‑stage biotech story: it has no product revenue yet and runs steady operating losses each year. The losses are relatively small in absolute corporate terms but persistent, reflecting ongoing spending on research, clinical trials, and overhead without any sales coming in. Earnings per share look extremely volatile, but that is largely a side effect of multiple reverse stock splits rather than dramatic swings in the underlying business. Overall, the income statement shows a company still firmly in the investment phase, not yet in a position to fund itself from operations.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base dominated by cash and almost no physical assets or long‑term debt. Equity has been drifting down over time and most recently sits very thin, which highlights how cumulative losses have eroded the company’s capital base. Multiple reverse stock splits over the years point to long‑term pressure on the share price and the need to regularly tidy up the capital structure. The positive side is the lack of heavy leverage; the concern is the limited financial cushion and dependence on future funding to sustain operations and large trials.

Cash Flow

Cash Flow Cash flow reflects the same pattern: regular cash outflow from operations and no offsetting inflow from product sales. Spending is focused on running the business and advancing the pipeline, with no meaningful investment in hard assets, which is typical for a platform biotech. Free cash flow is consistently negative, meaning the company relies on external capital – equity raises or partnerships – to keep moving its programs forward. This dependence on the capital markets is a central financial risk, especially as the company approaches more expensive late‑stage trials.

Competitive Edge

Competitive Edge Competitively, Imunon is small but differentiated. Its non‑viral, DNA‑based platforms for cancer therapies and vaccines give it a clear scientific angle versus more common viral vector or mRNA approaches. A lead ovarian cancer program with encouraging mid‑stage data, plus in‑house manufacturing capabilities, provides some real strengths for a company of this size. At the same time, it operates in extremely crowded and well‑funded fields – oncology and vaccinology – where larger players have deeper resources, and success often hinges on a handful of pivotal trial readouts. Execution on late‑stage trials and securing partnerships will be key to strengthening its position.

Innovation and R&D

Innovation and R&D Innovation is the core of Imunon’s story. The TheraPlas platform aims to turn tumors more visible to the immune system by delivering immune‑stimulating DNA directly to the tumor, while the PlaCCine platform targets longer‑lasting, more stable DNA vaccines that can be stored more easily than many current options. The company’s pipeline is still early, but it spans ovarian cancer, other difficult tumors, and infectious‑disease vaccines, including a COVID‑19 proof of concept. In‑house GMP manufacturing is a notable asset, letting Imunon control quality and timelines. The flip side is concentration risk: the value of the entire R&D effort is highly sensitive to a few key clinical programs and the evolving scientific view of non‑viral DNA approaches.

Summary

Imunon is a pre‑revenue, clinical‑stage biotech with a narrow but distinctive technological focus and a very lean financial profile. On the strength side, it offers differentiated non‑viral DNA platforms, a lead oncology candidate with promising intermediate results in an area of high unmet need, and internal manufacturing capabilities unusual for a company of its size. On the risk side, the business has no sales, consistent losses, a small capital base, and full reliance on external funding to continue trials. Future value will largely depend on the outcome of pivotal studies, the ability to secure partnerships around its platforms, and access to capital. This combination creates a high‑uncertainty, high‑risk profile typical of small, clinical‑stage biotechnology firms, where outcomes can change materially with a single major trial or deal.

NEWS

November 13, 2025 · 7:45 AM UTC

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 10, 2025 · 1:30 PM UTC

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Read more

November 10, 2025 · 7:30 AM UTC

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Read more

November 7, 2025 · 8:05 AM UTC

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Read more

November 6, 2025 · 8:05 AM UTC

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Read more